Nevro: Spinal Cord Stimulation for Diabetic Neuropathy in New Treatment Guidelines

  Nevro Corp (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Nevro's HFX 10 kHz Therapy is the only form of spinal cord stimulation (SCS) therapy to be referenced by the American Association of Clinical Endocrinology (AACE) in its 2022 Diabetes Clinical Practice Guideline to treat painful diabetic neuropathy (PDN).

Based on results from Nevro's landmark SENZA-PDN randomized controlled study, the AACE guideline states that high frequency (e.g., 10 kHz) spinal cord stimulation is a nonpharmacological approach that may be effective in persons with painful diabetic peripheral neuropathy that failed at least one medication.¹^,²  The treatment algorithm in the guideline also includes a referral to a pain physician for assessment if medical therapy has failed.   

https://www.biospace.com/article/releases/nevro-announces-american-association-of-clinical-endocrinology-clinical-practice-guideline-has-been-updated-to-include-high-frequency-10-khz-spinal-cord-stimulation-to-treat-painful-diabetic-neuropathy/